Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.

Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV.

Mol Cancer Res. 2004 Oct;2(10):541-50.

2.

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.

3.

Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. a pilot study.

Boehm BO, Lang G, Feldmann B, Kurkhaus A, Rosinger S, Volpert O, Lang GK, Bouck N.

Horm Metab Res. 2003 Jun;35(6):382-6.

PMID:
12920663
4.

Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas.

Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE.

Nat Med. 2003 Jun;9(6):774-80. Epub 2003 May 12.

PMID:
12740569
5.

Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy.

Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N.

Diabetologia. 2003 Mar;46(3):394-400. Epub 2003 Mar 1.

PMID:
12687338
7.

PEDF: anti-angiogenic guardian of ocular function.

Bouck N.

Trends Mol Med. 2002 Jul;8(7):330-4. Review.

PMID:
12114112
8.

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP.

Nat Med. 2002 Apr;8(4):349-57.

PMID:
11927940
9.

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC.

Int J Cancer. 2002 Apr 10;98(5):682-9.

10.

Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity.

Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, De Vries GH, Abramson LP, Bouck N.

J Cell Sci. 2001 Dec;114(Pt 24):4421-8.

11.

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.

Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP.

Prostate. 2001 Dec 1;49(4):293-305.

PMID:
11746276
12.

Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.

Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO.

Am J Pathol. 2001 Nov;159(5):1949-56.

13.

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N.

Oncogene. 2001 Jun 7;20(26):3443-8.

14.

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F.

Genes Dev. 2001 Jun 1;15(11):1373-82.

15.

The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.

Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC.

J Urol. 2001 Jun;165(6 Pt 1):2075-81.

PMID:
11371931
16.

Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.

Stellmach V, Crawford SE, Zhou W, Bouck N.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2593-7. Epub 2001 Jan 23.

17.

Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.

Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Lüttges J, Klöppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9.

18.

A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.

Gradishar WJ, Soff G, Liu J, Cisneros A, French S, Rademaker A, Benson AB 3rd, Bouck N.

Oncology. 2000 May;58(4):324-33.

PMID:
10838499
19.

Maspin is an angiogenesis inhibitor.

Zhang M, Volpert O, Shi YH, Bouck N.

Nat Med. 2000 Feb;6(2):196-9.

PMID:
10655109
20.

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N.

Nat Med. 2000 Jan;6(1):41-8.

PMID:
10613822
21.

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP.

Science. 1999 Jul 9;285(5425):245-8.

22.

Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function.

Gillis P, Savla U, Volpert OV, Jimenez B, Waters CM, Panos RJ, Bouck NP.

J Cell Sci. 1999 Jun;112 ( Pt 12):2049-57.

23.

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP.

Mol Pharmacol. 1999 Feb;55(2):332-8.

PMID:
9927626
25.

Multiple forms of angiostatin induce apoptosis in endothelial cells.

Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS.

Blood. 1998 Dec 15;92(12):4730-41.

PMID:
9845539
26.

The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo.

Vogler WR, Liu J, Volpert O, Ades EW, Bouck N.

Cancer Invest. 1998;16(8):549-53.

PMID:
9844614
27.

Inhibition of angiogenesis by interleukin 4.

Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP.

J Exp Med. 1998 Sep 21;188(6):1039-46.

28.

Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N.

Cell. 1998 Jun 26;93(7):1159-70.

29.

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

Volpert OV, Lawler J, Bouck NP.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6343-8.

30.

Anti-cancer dividends from captopril and other inhibitors of angiogenesis.

Bouck N, Campbell S.

J Nephrol. 1998 Jan-Feb;11(1):3-4. No abstract available.

PMID:
9561478
31.

Molecular mediators of angiogenesis in bladder cancer.

Campbell SC, Volpert OV, Ivanovich M, Bouck NP.

Cancer Res. 1998 Mar 15;58(6):1298-304.

32.

Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.

Koch AE, Szekanecz Z, Friedman J, Haines GK, Langman CB, Bouck NP.

Clin Immunol Immunopathol. 1998 Feb;86(2):199-208.

PMID:
9473383
33.

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10868-72.

34.

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP.

J Cell Biol. 1997 Aug 11;138(3):707-17.

35.
36.
37.

The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation.

Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ.

Carcinogenesis. 1997 Feb;18(2):329-38.

PMID:
9054625
38.

Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.

Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP.

Cancer Res. 1996 Dec 15;56(24):5684-91.

39.

Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts.

Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N.

Eur J Cancer. 1996 Dec;32A(14):2394-400. No abstract available.

PMID:
9059327
40.

Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA.

Cancer Res. 1996 Nov 1;56(21):4887-90.

41.

A novel simian virus 40 early-region domain mediates transactivation of the cyclin A promoter by small-t antigen and is required for transformation in small-t antigen-dependent assays.

Porrás A, Bennett J, Howe A, Tokos K, Bouck N, Henglein B, Sathyamangalam S, Thimmapaya B, Rundell K.

J Virol. 1996 Oct;70(10):6902-8.

42.

The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis.

Volpert O, Jackson D, Bouck N, Linzer DI.

Endocrinology. 1996 Sep;137(9):3871-6.

PMID:
8756559
43.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP.

J Clin Invest. 1996 Aug 1;98(3):671-9.

44.
45.

P53 and angiogenesis.

Bouck N.

Biochim Biophys Acta. 1996 May 16;1287(1):63-6. No abstract available.

PMID:
8639707
46.
47.

How tumors become angiogenic.

Bouck N, Stellmach V, Hsu SC.

Adv Cancer Res. 1996;69:135-74. Review. No abstract available.

PMID:
8791681
48.

Inhibition of angiogenesis by thrombospondin-2.

Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N.

Biochem Biophys Res Commun. 1995 Dec 5;217(1):326-32.

PMID:
8526929
49.

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.

Volpert OV, Stellmach V, Bouck N.

Breast Cancer Res Treat. 1995;36(2):119-26. Review.

PMID:
8534861
50.

Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein.

Jackson D, Volpert OV, Bouck N, Linzer DI.

Science. 1994 Dec 2;266(5190):1581-4.

PMID:
7527157

Supplemental Content

Support Center